Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.KLY


Primary Symbol: KALTF

Healthcare Biotechnology Cannabis
Kalytera Therapeutics Inc is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada. It develops new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering human therapeutics.


OTCPK:KALTF - Post by User

Claritas Pharmaceuticals Inc > New Kaly Website
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Comment by 011Pekingon Feb 07, 2021 7:10am
67 Views
Post# 32495025

RE:New Kaly Website

RE:New Kaly WebsiteThe site doesn't work anymore??? It worked for me yesterday but today i get directed to some "wordpress" login site or back to kalyteras old site... why?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities